Innovita Biological Technology Co., Ltd. (688253.SS) has a MoatMap StockRank of 42/100 based on Quality (66/100), Value (14/100), and Momentum (49/100) factor scores. The current signal is HOLD. Innovita Biological Technology specializes in diagnostic test kits. It lacks structural pricing power, has a highly commoditized product portfolio, and does not align with our CDMO or advanced packaging themes.
Innovita Biological Technology is a biotechnology company specializing in point-of-care testing (POCT) and diagnostic reagents, particularly for respiratory infectious diseases. The company's competitive moat is sustained by its rapid-response diagnostic platforms and extensive distribution channels across Chinese hospitals. It is a prominent niche player in the domestic in-vitro diagnostics (IVD) market.
| Price | $8.40 |
| Market Cap | $1.1B |
| P/E (TTM) | 87.21 |
| Price/Book | 3.70 |
| Return on Equity | 4.3% |
| Return on Invested Capital | 7.8% |
| Debt/Equity | 0.45 |
| Gross Margin | 73.2% |
| Operating Margin | 38.0% |
| Revenue Growth | -47.4% |
| Dividend Yield | 1.0% |
| Free Cash Flow | $198K |
Innovita Biological Technology Co., Ltd. operates in the Biotechnology industry, part of the Healthcare sector (China).